

Enantioselective Synthesis of Dialkylated *N*-Heterocycles by Palladium-Catalyzed Allylic Alkylation

Yoshitaka Numajiri,[†] Gonzalo Jiménez-Osés,[‡] Bo Wang,[§] K. N. Houk,[‡] and Brian M. Stoltz^{*,†}


[†]The Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, MC 101-20, Pasadena, California 91125, United States

[‡]Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States

[§]BioTools, Inc., 17546 Bee Line Highway, Jupiter, Florida 33458, United States

S Supporting Information

ABSTRACT: The enantioselective synthesis of α -disubstituted *N*-heterocyclic carbonyl compounds has been accomplished using palladium-catalyzed allylic alkylation. These catalytic conditions enable access to various heterocycles, such as morpholinone, thiomorpholinone, oxazolidin-4-one, 1,2-oxazepan-3-one, 1,3-oxazinan-4-one, and structurally related lactams, all bearing fully substituted α -positions. Broad functional group tolerance was explored at the α -position in the morpholinone series. We demonstrate the utility of this method to readily access a number of enantioenriched compounds.



This method by performing various transformations on our useful products to readily access a number of enantioenriched compounds.

N,O-Heterocycles such as morpholine, oxazolidine, and isoxazolidine are important pharmacophores in medicinal chemistry (Figure 1).^{1–11} Notable morpholine-containing




Figure 1. Representative *N,O*-heterocyclic-containing pharmaceuticals and natural products.

pharmaceuticals include edivoxetine,² an antidepressant and a treatment for ADHD; linezolid,⁶ a synthetic antibiotic; and gefitinib,⁵ an EGFR inhibitor used to treat certain breast, lung, and other cancers. Five-membered isoxazolidinone is the core structure of cycloserine,⁹ an antibiotic for the treatment of tuberculosis. Quinocarcin,⁸ possessing an oxazolidine ring in the 3,8-diazabicyclo[3.2.1]octane framework, has shown remarkable antiproliferative activity against lymphocytic leukemia. An antibiotic, FR-66979,¹⁰ isolated from *Streptomyces sandaensis* No. 6897, contains a 1,2-oxazinanone moiety.

In addition to a wide variety of biological activity, *N,O*-heterocycles shown in Figure 2 are commonly used as synthetic




Figure 2. α -Tertiary and quaternary *N,O*-heterocycles.

intermediates, which provide various hydroxy acid moieties after acetal removal or N–O bond cleavage. Oxazolidin-4-ones have been reported as good platforms to α -hydroxyacids.¹² For example, Ye et al.^{12a} reported that the formal [3 + 2] cycloaddition between ketenes and oxaziridines could be applied in an enantioselective fashion to synthesize oxazolidin-4-one derivatives, which could be converted into the corresponding α -hydroxy acids. 1,2-Oxazinan-3-ones have

Received: November 25, 2014

Revised: February 11, 2015

proved to be excellent precursors to γ -hydroxy acid and γ -butyrolactone derivatives.¹³

Our group has a sustained interest in the enantioselective synthesis of α -quaternary carbonyl compounds,^{14–16} which offers a novel solution for these challenging chiral centers in natural product synthesis. Influenced by our results, the Lupton group^{17a} and the Shao group^{17b} simultaneously reported that carbazolones are suitable substrates under our allylic alkylation conditions and applied the resulting chiral building blocks to total syntheses of indole alkaloids. Significant work in our laboratory has identified conditions for the enantioselective allylic alkylation to provide α -quaternary lactams in exceptional yields and enantioselectivities.^{14b} As part of that endeavor, we reported that 2-allyl-2-methylmorpholin-3-one **2a** was obtained in a similar manner in high yield (91% yield) and outstanding enantioselectivity (99% ee). We sought to extend the substrate scope to morpholine derivatives and postulated that a broadly expanded array of chiral *N,O*-heterocycles might be readily accessible using our palladium-catalyzed allylic alkylation. Herein, we describe the enantioselective allylic alkylation of heterocycles, including morpholin-3-one, thiomorpholine-3-one, oxazolidin-4-one, 1,2-oxazepan-3-one, and 1,3-oxazinan-4-one.¹⁸ Furthermore, the enantioenriched products obtained were successfully converted into useful asymmetric building blocks containing quaternary and tetrasubstituted tertiary chiral centers.

We prepared a collection of racemic morpholinone substrates **1a–e**¹⁹ and performed palladium-catalyzed decarboxylative allylic alkylation with Pd₂(dba)₃ (5 mol %) and (*S*)-(CF₃)₃-*t*-BuPHOX (12.5 mol %, PHOX = phosphinooxazoline) in a 0.033 M solution of toluene (Figure 3). Simple α -benzyl substitution performed well in this chemistry; the desired 2-benzyl α -tetrasubstituted morpholinone **2b** was obtained in 95% yield and 99% ee. Gratifyingly, other functionalized substrates (benzyl ether, methyl ester, nitrile) are well tolerated, affording α -functionalized morpholinones **2c**, **2d**, and **2e** in uniformly excellent enantioenrichment (99% ee), although the yield of **2d** was moderate (60%). Having demonstrated a broad functional group tolerance within the side chain, we explored other ring sizes and frameworks. Replacement of oxygen with sulfur gave thiomorpholinone **2f** in good yield, but slightly decreased enantioselectivity (79% yield, 86% ee). Like morpholinone, benzomorpholinone is also a good substrate class, delivering allylated product **2g** in 76% yield and 95% ee. Additionally, α -tetrasubstituted oxazolidin-4-one **2h** is produced in 82% yield and 96% ee with higher temperature applied (60 °C).²¹ Benzylloxazolinone **2i** is also produced in good yield and enantioselectivity.

With excellent results on α,α -dialkyl 2-oxa- and thia-linked lactams in hand, we started to investigate allylic alkylation using cyclic hydroxamic acid derivatives to obtain α -quaternary *N,O*-heterocycles (Table 1). Isoxazolidin-3-one **3a** (R = Bz), **3b** (R = Boc), and **3c** (R = CO₂Ph) produced the desired alkylated compounds **4a–c** in excellent yields (95–98%), but with modest enantioselectivities (72–73% ee) (entries 1–3). Benzoyl protected 1,2-oxazinan-3-one **3d** underwent an unexpected side reaction and produced only small amounts of **4d** (entry 4).²⁴ Despite the low yield, the enantioselectivity of **4d** is still satisfactory (88% ee), which encouraged us to identify an effective *N*-protecting group to circumvent the undesired reaction. A bulky pivaloyl group somehow suppresses the side reaction, but decreases the enantioselectivity (entry 5). An electron-rich *N*-benzylated **3f** was a poor substrate for




Figure 3. Substrate scope of α -tertiary heterocycles. ^a Reaction performed with 0.1 mmol of **1**, 5 mol % of Pd₂(dba)₃, 12.5 mol % of (*S*)-(CF₃)₃-*t*-BuPHOX at 0.033 M in toluene at 50 °C. ^b Determined by chiral SFC analysis. ^c Reactions were performed on **1g**, **1h**, and **1i** at 60 °C. ^d The ee of **2g** was determined by chiral SFC analysis after Bz removal (see Supporting Information). ^e Pd₂(pmdba)₃ (pmdba = bis(4-methoxybenzylidene)acetone) was used instead of Pd₂(dba)₃. ^f Absolute configuration was assigned by vibrational circular dichroism (VCD) spectroscopy²² supported by theoretical calculations (see Supporting Information). ^g Absolute stereochemistry assigned by conversion into (–)-methyl 2-hydroxy-2-methylpent-4-enoate.²³

decarboxylative alkylation (entry 6).²⁵ Finally, we discovered that carbamates **3g–i** produced the desired products in good yields (67–89%) and acceptable enantioselectivities (84–87% ee) (entries 7–9), with little or none of the undesired side reactivity observed. We were delighted to find that seven-membered **3j** is an excellent substrate in this class, furnishing **4j** in a good yield and excellent enantioselectivity (entry 10, 81% yield, 93% ee).

As shown in Scheme 1, we have also demonstrated allylic alkylation with 1,3-oxazinan-4-one **5** as an alternative β -hydroxy acid synthon of **3a**. To our delight, **5** was successfully converted into **6** in 90% yield and 94% ee.


We anticipate that our newly developed heterocycles could play important roles in medicinal agent discovery and also serve as useful chiral building blocks. To demonstrate the value and versatility of this new class of α -tetrasubstituted heterocycles, we implemented a number of product transformations (Scheme 2). For example, removal of the benzoyl group followed by reduction using LiAlH₄ can readily convert morpholinone **2c** into *N*-H morpholine **7**. Acid treatment of **2h** in methanol provided α -tertiary-hydroxy ester **8** in 71% yield without erosion of enantiopurity.²⁶ α -Quaternary δ -lactone **9** was

Table 1. Substrate Scope of α -Quaternary Cyclic Hydroxamic Acid Derivatives^a


| entry | substrate | R | yield (%) ^b | ee (%) ^c |
|-------|-----------|-------------------------|------------------------|---------------------|
| 1 | | Bz (3a→4a) ^d | 98 | 73 |
| 2 | | Boc (3b→4b) | 95 | 72 |
| 3 | | PhO(CO) (3c→4c) | 95 | 73 |
| 4 | | Bz (3d→4d) | 29 | 88 |
| 5 | | Piv (3e→4e) | 48 | 73 |
| 6 | | Bn (3f→4f) | trace | ND |
| 7 | | Boc (3g→4g) | 67 | 85 |
| 8 | | Cbz (3h→4h) | 89 | 84 |
| 9 | | PhO(CO) (3i→4i) | 70 | 87 |
| 10 | | Bz (3j→4j) | 81 | 93 |

^aReaction performed under the conditions of Figure 3 at 60 °C. ^bAll reported yields are for isolated products. ^cEnantiomeric excesses were determined by chiral SFC analysis. ^dAbsolute configuration was assigned by VCD spectroscopy²² supported by theoretical calculations (see Supporting Information).

Scheme 1. Synthesis of 1,3-Oxazinan-4-one 6



Scheme 2. Derivatization of Allylic Alkylation Products



synthesized from 4j in a good yield by zinc mediated reduction of the N–O bond followed by acid catalyzed cyclization.

In conclusion, we have developed a variety of new classes of substrates for catalytic enantioselective allylic alkylation to generally form α,α -disubstituted 2-keto heterocycles, such as morpholinones, oxazolidinones, cyclic hydroxamic acid derivatives, and 1,3-oxazinanones. The asymmetric products formed in this communication are envisioned to be valuable pharmacophores in medicinal chemistry, and their trans-

formations afford a variety of important structures such as chiral hydroxy acid derivatives. Studies utilizing this method toward the synthesis of complex natural products and other bioactive small molecules are ongoing in our laboratory.

ASSOCIATED CONTENT

Supporting Information

Experimental procedures and compound characterization. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: Stoltz@caltech.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors wish to thank NIH-NIGMS (R01GM080269 to B.M.S. and R01GM075962 to K.N.H.), Amgen, the Gordon and Betty Moore Foundation, the Caltech Center for Catalysis and Chemical Synthesis, and Caltech for financial support. Y.N. thanks Toray Industries, Inc. for a postdoctoral fellowship. G.J.-O. and K.N.H. used the Extreme Science and Engineering Discovery Environment (XSEDE) supported by a grant (OCI-1053575) along with the UCLA Institute of Digital Research and Education (IDRE). The authors are grateful to Dr. Rina Dukor (BioTools) for helpful discussions. The authors thank Scott Virgil (Caltech) for instrumentation assistance and Dr. Douglas C. Behenna (Caltech) and Mr. Beau Pritchett (Caltech) for initial experimental results.

REFERENCES

- (1) For reviews, see: (a) Wijnmans, R.; Vink, M. K. S.; Schoemaker, H. E.; van Delft, F. L.; Blaauw, R. H.; Rutjes, F. P. J. T. *Synthesis* **2004**, 641. (b) Aroney, M.; le Fèvre, R. J. W. *J. Chem. Soc.* **1958**, 3002.
- (2) (a) Dubé, S.; Dellva, M. A.; Jones, M.; Kielbasa, W.; Padich, R.; Saha, A.; Rao, P. *J. Psychiatr. Res.* **2010**, *44*, 356. (b) Pangallo, B.; Dellva, M. A.; D'Souza, D. N.; Essink, B.; Russell, J.; Goldberger, C. *J. Psychiatr. Res.* **2011**, *45*, 748.
- (3) Hale, J. J.; Mills, S. G.; MacCoss, M.; Finke, P. E.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Chicchi, G. G.; Kurtz, M.; Metzger, J.; Eiermann, G.; Tsou, N. N.; Tattersall, F. D.; Rupniak, N. M. J.; Williams, A. R.; Rycroft, W.; Hargreaves, R.; MacIntyre, D. E. *J. Med. Chem.* **1998**, *41*, 4607.
- (4) (a) Morie, T.; Kato, S.; Harada, H.; Yoshida, N.; Matsumoto, J. *Chem. Pharm. Bull.* **1994**, *42*, 877. (b) Mine, Y.; Yoshikawa, T.; Oku, S.; Nagai, R.; Yoshida, N.; Hosoki, K. *J. Pharmacol. Exp. Ther.* **1997**, *283*, 1000.
- (5) (a) Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1911. (b) Sirotnak, F. M.; Zakowski, M. F.; Miller, V. A.; Scher, H. I.; Kris, M. G. *Clin. Cancer Res.* **2000**, *6*, 4885.
- (6) Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D. A.; Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G. E. *J. Med. Chem.* **1996**, *39*, 673.
- (7) Cang, S.; Ohta, S.; Chiba, H.; Johdo, O.; Nomura, H.; Nagamatsu, Y.; Yoshimoto, A. *J. Antibiot.* **2001**, *54*, 304.
- (8) (a) Tomita, F.; Takahashi, K.; Shimizu, K. *J. Antibiot.* **1983**, *36*, 463. (b) Takahashi, K.; Tomita, F. *J. Antibiot.* **1983**, *36*, 468.
- (9) (a) Tomita, F.; Takahashi, K.; Tamaoki, T. *J. Antibiot.* **1984**, *37*, 1268.
- (9) (a) Epstein, I. G.; Nair, K. G.; Boyd, L. J. *J. Antibiot. Med. Clin. Ther.* **1955**, *1*, 80. (b) Welch, H.; Putnam, L. E.; Randall, W. A. *J. Antibiot.*

Med. Clin. Ther. **1955**, *1*, 72. (c) Hidy, P. H.; Hodge, E. B.; Young, V. V.; Harned, R. L.; Brewer, G. A.; Phillips, W. F.; Runge, W. F.; Stavely, H. E.; Pohland, A.; Boaz, H.; Sullivan, H. R. *J. Am. Chem. Soc.* **1955**, *77*, 2345. (d) Ressler, K. J.; Rothbaum, B. O.; Tannenbaum, L.; Anderson, P.; Graap, K.; Zimand, E.; Hodges, L.; Davis, M. *Arch. Gen. Psychiatry* **2004**, *61*, 1136.

(10) (a) Terano, H.; Takase, S.; Hosoda, J.; Kohsaka, M. *J. Antibiot.* **1989**, *42*, 145. (b) Rajski, S. R.; Rollins, S. B.; Williams, R. M. *J. Am. Chem. Soc.* **1998**, *120*, 2192.

(11) (a) Kuehne, M. E.; Konopka, E. A. *J. Med. Chem.* **1962**, *5*, 257. (b) Chylińska, J. B.; Urbański, T.; Mordarski, M. *J. Med. Chem.* **1963**, *6*, 484.

(12) (a) Shao, P.-L.; Chen, X.-Y.; Ye, S. *Angew. Chem., Int. Ed.* **2010**, *49*, 8412. (b) Ooi, T.; Fukumoto, K.; Maruoka, K. *Angew. Chem., Int. Ed.* **2006**, *45*, 3839. (c) Cardillo, G.; Hashem, M. A.; Tomasini, C. *J. Chem. Soc., Perkin Trans. 1* **1990**, 1487. (d) Roush, W. R.; Essensfeld, A. P.; Warmus, J. S.; Brown, B. B. *Tetrahedron Lett.* **1989**, *30*, 7305.

(13) (a) Ranganathan, S.; Ranganathan, D.; Mehrotra, A. K. *J. Am. Chem. Soc.* **1974**, *96*, 5261. (b) Clarke, P. A.; Cridland, A. P.; Rolla, G. A.; Iqbal, M.; Bainbridge, N. P.; Whitwood, A. C.; Wilson, C. *J. Org. Chem.* **2009**, *74*, 7812.

(14) (a) Behenna, D. C.; Mohr, J. T.; Sherden, N. H.; Marinescu, S. C.; Harned, A. M.; Tani, K.; Seto, M.; Ma, S.; Novak, Z.; Krout, M. R.; McFadden, R. M.; Roizen, J. L.; Enquist, J. A., Jr.; White, D. E.; Levine, S. R.; Petrova, K. V.; Iwashita, A.; Virgil, S. C.; Stoltz, B. M. *Chem.—Eur. J.* **2011**, *17*, 14199. (b) Behenna, D. C.; Liu, Y.; Yurino, T.; Kim, J.; White, D. E.; Virgil, S. C.; Stoltz, B. M. *Nat. Chem.* **2012**, *4*, 130. (c) Bennett, N. B.; Duquette, D. C.; Kim, J.; Liu, W.-B.; Marziale, A. N.; Behenna, D. C.; Virgil, S. C.; Stoltz, B. M. *Chem.—Eur. J.* **2013**, *19*, 4414. (d) Reeves, C. M.; Eidamshaus, C.; Kim, J.; Stoltz, B. M. *Angew. Chem., Int. Ed.* **2013**, *52*, 6718.

(15) (a) Liu, W.-B.; Reeves, C. M.; Virgil, S. C.; Stoltz, B. M. *J. Am. Chem. Soc.* **2013**, *135*, 10626. (b) Liu, W.-B.; Reeves, C. M.; Stoltz, B. M. *J. Am. Chem. Soc.* **2013**, *135*, 17298.

(16) Ma, S.; Han, X.; Krishnan, S.; Virgil, S. C.; Stoltz, B. M. *Angew. Chem., Int. Ed.* **2009**, *48*, 8037.

(17) (a) Gartshore, C. J.; Lupton, D. W. *Angew. Chem., Int. Ed.* **2013**, *52*, 4113. (b) Li, Z.; Zhang, S.; Wu, S.; Shen, X.; Zou, L.; Wang, F.; Li, X.; Peng, F.; Zhang, H.; Shao, Z. *Angew. Chem., Int. Ed.* **2013**, *52*, 4117.

(18) For examples of α,α -dialkylated ketopiperazine synthesis, see: Korch, K. M.; Eidamshaus, C.; Behenna, D. C.; Nam, S.; Horne, D.; Stoltz, B. M. *Angew. Chem., Int. Ed.* **2015**, *54*, 179.

(19) For preparation of substrates, see ref 14b and Supporting Information.


(20) McDougal, N. T.; Streuff, J.; Mukherjee, H.; Virgil, S. C.; Stoltz, B. M. *Tetrahedron Lett.* **2010**, *51*, 5550.

(21) The substrate **1h** can be readily prepared from commercially available lactamide in three steps.¹⁹

(22) Stephens, P. J.; Devlin, F. J.; Cheeseman, J. R. *VCD Spectroscopy for Organic Chemists*; CRC Press: Boca Raton, FL, 2012.

(23) Seto, M.; Roizen, J. L.; Stoltz, B. M. *Angew. Chem., Int. Ed.* **2008**, *47*, 6873.

(24) We isolated **10** presumably due to retro [4 + 2] cycloaddition followed by palladium-catalyzed alkylation.



(25) We also observed that electron-rich *N*-alkyl protection of amides decreased the reactivity under our conditions; see ref 14b.

(26) For an alternative preparation of α -tertiary-hydroxy carbonyl compounds, see ref 23.